Every Form 4 that ImageneBio, Inc. (IMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received equity awards on August 14, 2026. She was granted 254,800 shares of Common Stock in the form of restricted stock units, which begin vesting on April 14, 2027 and continue in quarterly installments, subject to continued service. She was also granted two employee stock option awards covering 137,200 shares and 250,000 shares of Common Stock at an exercise price of $5.84 per share, each vesting over four years under specified monthly schedules. Following the RSU grant, she directly owned 493,705 Common shares.
ImageneBio, Inc. reported equity compensation awards to its Chief Financial Officer, Yanina Grant-Huerta. On August 14, 2026 she received a grant of 56,000 stock options with an exercise price of $5.84 per share, expiring on August 13, 2036. She also received a total of 104,000 restricted stock units, represented by two grants of 65,000 and 39,000 shares of common stock underlying RSUs. Footnotes state these updated awards replace a previously described but not yet granted package, and that 25% of both the RSUs and options vest on July 20, 2027 with the remainder vesting in equal periodic installments thereafter, subject to continued service.
ImageneBio, Inc. Chief Executive Officer Kristin Yarema reported RSU-related changes in ownership. On July 25, 2026, 38,376 restricted stock units were exercised into 38,376 shares of common stock at $0.0000 per share. An additional 115,129 unvested RSUs from a July 28, 2025 grant were reclassified and now appear as common stock holdings; no purchase or sale transactions are reported.
ImageneBio, Inc. Principal Accounting Officer Robert B. Lally reported selling a total of 3,196 shares of Common Stock in open-market transactions on July 16–17, 2026. Sales included 1,671 shares at a weighted average price of $5.50 (range $5.45–$5.635) and 1,525 shares at $5.34 (range $5.32–$5.3527).
ImageneBio, Inc. director Jonathan Jian Wang received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036.
The options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control under the 2025 Equity Incentive Plan.
ImageneBio, Inc. director Otello Stampacchia received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036. All 15,600 options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. Following this grant, Stampacchia holds 15,600 stock options directly.
ImageneBio, Inc. director Joseph P. Slattery reported receiving a stock option grant as equity compensation. The award covers 15,600 shares of common stock at an exercise price of $5.45 per share, expiring on June 16, 2036.
According to the terms, the option vests in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. After this grant, Slattery holds options for 15,600 shares directly.
ImageneBio, Inc. director Bonita P. David received a grant of stock options covering 15,600 shares of Common Stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036. They vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control as defined in ImageneBio’s 2025 Equity Incentive Plan. Following this award, the filing shows David holding 15,600 options directly, with no open-market buying or selling reported.
ImageneBio director–affiliated investment funds made a sizable indirect purchase of pre-funded warrants. On the April 14, 2026 closing of a private placement, OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P. acquired pre-funded warrants to buy a total of 721,292 shares of ImageneBio common stock at a price of $5.199 per warrant. These pre-funded warrants are exercisable at $0.001 per share and include a 19.99% beneficial ownership blocker. After the transactions, the OrbiMed funds also indirectly held 753,062 and 20,691 shares of common stock, and all entities, including director Bonita P. David, disclaim beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. reported that funds affiliated with OrbiMed purchased pre-funded warrants in a private placement. OrbiMed-related vehicles acquired pre-funded warrants to buy up to 721,292 shares of common stock at a price of $5.199 per warrant, with an exercise price of $0.001 per share.
The pre-funded warrants are exercisable at any time after issuance, subject to a 19.99% beneficial ownership blocker, and expire once fully exercised. The securities are held of record by OrbiMed Private Investments VI, LP and OrbiMed Genesis Master Fund, L.P., with OrbiMed entities and their principals disclaiming beneficial ownership beyond any pecuniary interest.
ImageneBio, Inc. reported that Chief Executive Officer Kristin Yarema received new equity awards as part of her compensation. She was granted an option to buy 128,100 shares of common stock at an exercise price of $6.20 per share, vesting over four years starting March 15, 2027. She also received 85,400 restricted stock units, each convertible into one share of common stock, with 25% vesting on March 15, 2027 and the rest in equal quarterly installments over the following three years, subject to continued service.
ImageneBio, Inc. reported that director Stephen Hui Wang acquired common stock on 07/25/2025 as part of a two-step merger that converted Legacy Inmagene preferred and ordinary shares into Issuer common stock at a ratio of 0.003051 per legacy share. The filing shows Mr. Wang's indirect holdings increased by 188,042 shares through entities he controls, plus additional indirect holdings of 50,144 and 12,535 shares via related vehicles. The transaction reflects the merger consideration and a corporate name change from Ikena Oncology, Inc. to ImageneBio, Inc.
The report discloses that the Form 4 was filed late due to delays obtaining EDGAR codes. The filing describes the chain of ownership: shares were received in exchange for Series C-1 and C-2 preferred shares of Legacy Inmagene, and voting/investment power over the reported holdings is exercised by Mr. Wang through HLC GP and affiliated entities.